Company Overview and News
Dan Loeb's 13F portfolio value increased 5.45% from $11.28B to $11.90B this quarter. The number of positions increased from 32 to 37. (1016-2)
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (647-3)
Today we look at Kadmon Holdings, a small biopharma concern that has not yet lived up to its promise. (27-0)
Sabby Management, Llc has disclosed 216 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 1,719,016,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Sabby Management, Llc's top holdings are Merck & Co., Inc. (NYSE:MRK) , Bristol-Myers Squibb Co. (OTC:BMYMP) , Bristol-Myers Squibb Co. (OTC:BMYMP) , AstraZeneca Plc (NYSE:AZN) , and AbbVie Inc. (369-17)
* Kadmon Holdings Inc prices offering of aggregate of 24,000,000 shares at a combined public offering price of $3.00 per share Source text for Eikon: Further company coverage: (27-0)
* Kadmon Holdings Inc - Intends to use net proceeds from offering for preclinical and clinical development of its lead product candidates Source text for Eikon: Further company coverage: (27-0)
* Kadmon Holdings Inc - on September 13, 2017, co dosed first patient in a phase 1 clinical study to evaluate safety and tolerability of Tesevatinib Source text: (bit.ly/2yoVQas) Further company coverage: (27-0)
Dan Loeb's 13F portfolio value increased ~10% from $10.25B to $11.28B this quarter. The number of positions decreased from 37 to 32. (0-2)
August 02, 2017 - Goldentree Asset Management Lp has filed a SC 13D/A form disclosing ownership of 7,007,712 shares of Kadmon Holdings, Inc. (NYSE:KDMN) corresponding to a(n) 12.9 ownership percentage. (0-1)
JPMorgan Chase & Co. raised its stake in Kadmon Holdings Inc (NASDAQ:KDMN) by 11,654.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 228,866 shares of the company’s stock after buying an additional 226,919 shares during the period. JPMorgan Chase & Co. owned approximately 0.44% of Kadmon Holdings worth $829,000 at the end of the most recent reporting period.
NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE: KDMN) (“Kadmon” or the “Company”) today announced supplemental clinical data from the first cohort (KD025 200 mg QD) of an ongoing Phase 2 clinical trial (KD025-208) of the Company’s lead Rho-associated coiled-coil kinase 2 (“ROCK2”) inhibitor, KD025, for chronic graft-versus-host disease (“cGVHD”). The Company first announced clinical data from the study on July 11, 2017. (0-1)
In a report issued on July 11, Edward Tenthoff from Piper Jaffray reiterated a Buy rating on Kadmon Holdings (NYSE: KDMN), with a price target of $7. The company’s shares closed yesterday at $3.14, close to its 52-week high of $11.73.
DELCATH SYS INC, BANK AMER CORP, NUTRA PHARMA CORP, ADVANCED MICRO DEVICES INC, RITE AID CORP, ANNALY CAP MGMT INC
NEW YORK, Apr 12, 2017 (BUSINESS WIRE) -- Kadmon Holdings, Inc. KDMN, -2.87% (“Kadmon” or the “Company”) today announced the publication of clinical data from its completed Phase 2 open-label clinical trial of KD025, its oral Rho-associated coiled-coil kinase 2 (“ROCK2”) inhibitor, in patients with moderate to severe psoriasis. In the study, KD025 treatment improved clinical scores and skin pathology in psoriasis patients via concurrent modulation of the pro- and anti-inflammatory immune cell response.
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton